FibroGen is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics to treat serious unmet medical needs. The company specializes in fibrosis, anemia, and oncology, with a particular focus on hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) pathways. FibroGen went public in 2013 and has developed several drug candidates including roxadustat for anemia and pamrevlumab for fibrotic diseases. The company has partnerships with major pharmaceutical companies and has advanced multiple compounds through clinical trials.
FibroGen has received investment from 1 venture capital firm.
| Date | Round | Amount | Lead Investor |
|---|---|---|---|
| Aug 2025 | Growth | $320M | Wellington Management Ventures |
Biopharmaceutical company focused on developing therapies for fibrotic diseases, anemia, and cancer through innovative drug discovery.
FibroGen has received investment from Versant Ventures. These venture capital firms and investors provide both capital and strategic support.
FibroGen was founded in 1993 and is headquartered in San Francisco, CA.
FibroGen operates in the Biotech sector. Biopharmaceutical company focused on developing therapies for fibrotic diseases, anemia, and cancer through innovative drug discovery.
